



NNHLA

National Non-Hodgkin
Lymphoma Audit

NNHLA State of the Nation Report 2024
Supplementary tables

Supplementary Table 1 - Characteristics of people with NHL in England (2020 and 2021)¹ and for Wales (2022)

	Jan - Dec 2020 England		Jan - Dec 2021 England		Jan - Dec 2022 Wales	
	N	%	N	%	N	%
Total	14,099	100	14,973	100	619	100
Age at diagnosis						
Mean (standard deviation (SD))	68.8 (13.8)		69.0 (13.9)		69.1 (12.7)	
18-59	3,131	22.2	3,365	22.5	124	20.0
60-69	3,251	23.1	3,194	21.3	153	24.7
70-79	4,565	32.4	5,014	33.5	216	34.9
80+	3,152	22.4	3,400	22.7	126	20.4
Sex						
Male	8,201	58.2	8,578	57.3	324	59.8
Female	5,898	41.8	6,395	42.7	218	40.2
Missing (% of total)	0 (0)		0 (0)		77 (12.4)	
Ethnicity						
White/White British	12,280	91.6	12,612	91.4	280	98.9
Asian/Asian British	543	4.1	568	4.1	<5	<0.1
Black/Black British	276	2.1	287	2.1	-	-
Mixed	72	0.5	82	0.6	-	-
Other	240	1.8	243	1.8	<5	<0.1
Missing (% of total)	688 (4.9)		1,181 (7.9)		336 (54.3)	
IMD quintiles						
1 - most deprived	2,113	15.0	2,287	15.3	80	14.2
2	2,612	18.5	2,622	17.5	126	22.4
3	2,914	20.7	3,207	21.4	110	19.5
4	3,161	22.4	3,383	22.6	111	19.7
5 - least deprived	3,299	23.4	3,474	23.2	136	24.2
Missing (% of total)	0 (0)		0 (0)		56 (9.1)	
Performance status						
0 (fully active)	3,310	49.0	3,639	48.9	184	49.3
1	2,211	32.7	2,379	32.0	110	29.5
2	716	10.6	869	11.7	41	11.0
3 to 5 (limited or no selfcare or deceased)	521	7.7	550	7.4	38	10.2
Missing (% of total)	7,341 (52.1)		7,536 (50.3)		246 (39.7)	
Charlson Comorbidity Index						
0	4,674	47.7	4,807	47.7	223	60.3
1	2,836	28.9	2,880	28.6	92	24.9



2	1,349	13.8	1,350	13.4	35	9.5
3+	943	9.6	1,048	10.4	20	5.4
Missing (% of total)	4,297 (30.5)		4,888 (32.7)		249 (40.2)	

Supplementary Table 2 – Tumour characteristics (sub-type) in England (2020 and 2021)¹ and Wales (2022)

	Jan – Dec 2020 England		Jan – Dec 2021 England		Jan – Dec 2022 Wales	
	N	%	N	%	N	%
Total	14,099	100	14,973	100	619	100
NHL type						
<i>Mature B-cell neoplasms</i>						
Burkitt lymphoma	115	0.8	121	0.8	<5*	<0.8
Chronic lymphocytic leukaemia	3,092	21.9	3,367	22.5	157	25.4
Follicular lymphoma	2,097	14.9	2,287	15.3	117	18.9
Large B-cell lymphomas	4,280	30.4	4,209	28.1	199	32.2
Mantle cell lymphoma	503	3.6	550	3.7	27	4.4
Marginal zone lymphoma	1,141	8.1	1,213	8.1	17	2.8
NHL, not otherwise specified (NOS)	1,029	7.3	1,161	7.8	33	5.3
<i>Mature T- and NK-cell neoplasms</i>						
Cutaneous T-cell lymphomas	294	2.1	316.0	2.1	15	2.4
Peripheral T-cell lymphomas	557	4.0	615.0	4.1	18	2.9
<i>Other</i>	991	7.0	1,134	7.6	~35*	~5

* Exact numbers suppressed to protect people's confidentiality

Supplementary Table 3 - MDT discussion within 4 weeks of diagnosis for individual sub-type of NHL in England¹: Percentages are amongst people with MDT status available.

Denominator*	England 2020	Variation 2020	England 2021	Variation 2021
Burkitt lymphoma	89.9%	Range: 0-100% Median (IQR): 100% (100-100%)	82.8%	Range: 0-100% Median (IQR): 100% (100-100%)
Chronic lymphocytic leukaemia	63.0%	Range: 0-100% Median (IQR): 63% (46-80%)	58.1%	Range: 0-100% Median (IQR): 60% (44-74%)
Follicular lymphoma	65.1%	Range: 0-100% Median (IQR): 65% (50-80%)	59.7%	Range: 0-100% Median (IQR): 60% (44-74%)
Large B-cell lymphomas	77.5%	Range: 0-100% Median (IQR): 79% (67-88%)	71.5%	Range: 0-100% Median (IQR): 71% (59-83%)

¹ Data were impacted by the COVID-19 pandemic and so will be atypical to some degree during 2020-2021



NNHLA

National Non-Hodgkin
Lymphoma Audit

Mantle cell lymphoma	73.9%	Range: 0-100% Median (IQR): 75% (57-100%)	68.1%	Range: 0-100% Median (IQR): 75% (50-100%)
Marginal zone lymphoma	51.5%	Range: 0-100% Median (IQR): 50% (30-67%)	49.3%	Range: 0-100% Median (IQR): 50% (33-67%)
NHL, NOS	70.4%	Range: 0-100% Median (IQR): 75% (50-100%)	62.3%	Range: 0-100% Median (IQR): 67% (50-76%)
Peripheral T-cell lymphomas	68.0%	Range: 0-100% Median (IQR): 71% (50-100%)	63.5%	Range: 0-100% Median (IQR): 67% (40-100%)
Cutaneous T-cell lymphomas	45.0%	Range: 0-100% Median (IQR): 42% (0-100%)	38.3%	Range: 0-100% Median (IQR): 27% (0-67%)
Other	72.0%	Range: 0-100% Median (IQR): 75% (50-100%)	70.2%	Range: 0-100% Median (IQR): 73% (50-96%)

* Denominator is number of people (with NHL) with MDT status available. Available in 73.0% and 72.6% for England in 2020 and 2021, respectively.

** Interquartile range (IQR)

Supplementary Table 4 - MDT discussion within 8 weeks of diagnosis for individual sub-type of NHL in England². Percentages are amongst people with MDT status available.

Denominator	England 2020	Variation 2020	England 2021	Variation 2021
All people with NHL	89.9%	Range: 0-100% Median (IQR): 91% (86-93%)	87.0%	Range: 0-100% Median (IQR): 88% (83-92%)
High-grade lymphoma	92.9%	Range: 0-100% Median (IQR): 93% (90-97%)	91.0%	Range: 0-100% Median (IQR): 92% (87-96%)
Low-grade lymphoma	86.2%	Range: 0-100% Median (IQR): 88% (79-93%)	82.3%	Range: 0-100% Median (IQR): 84% (77-89%)
Burkitt lymphoma	100%	Range: 100-100% Median (IQR): 100% (100-100%)	95.4%	Range: 0-100% Median (IQR): 100% (100-100%)
Chronic lymphocytic leukaemia	84.3%	Range: 0-100% Median (IQR): 86% (75-95%)	80.2%	Range: 0-100% Median (IQR): 81% (73-93%)
Follicular lymphoma	90.3%	Range: 0-100% Median (IQR): 92% (83-100%)	87.0%	Range: 43-100% Median (IQR): 89% (83-96%)

² Data were impacted by the COVID-19 pandemic and so will be atypical to some degree during 2020-2021



NNHLA

National Non-Hodgkin
Lymphoma Audit

Large B-cell lymphomas	94.8%	Range: 0-100% Median (IQR): 96% (92-100%)	93.2%	Range: 0-100% Median (IQR): 95% (90-100%)
Mantle cell lymphoma	93.2%	Range: 0-100% Median (IQR): 100% (90-100%)	93.2%	Range: 50-100% Median (IQR): 100% (93-100%)
Marginal zone lymphoma	82.4%	Range: 0-100% Median (IQR): 86% (71-100%)	77.9%	Range: 0-100% Median (IQR): 82% (67-100%)
NHL, NOS	89.0%	Range: 0-100% Median (IQR): 100% (80-100%)	85.5%	Range: 0-100% Median (IQR): 88% (75-100%)
Peripheral T-cell lymphomas	87.3%	Range: 0-100% Median (IQR): 100% (75-100%)	87.8%	Range: 0-100% Median (IQR): 100% (80-100%)
Cutaneous T-cell lymphomas	74.5%	Range: 0-100% Median (IQR): 100% (60-100%)	65.0%	Range: 0-100% Median (IQR): 73% (0-100%)
Other	90.4%	Range: 0-100% Median (IQR): 100% (86-100%)	89.5%	Range: 0-100% Median (IQR): 100% (82-100%)

Supplementary Table 5: Proportion of people diagnosed with NHL receiving radiotherapy at any point from diagnosis, reported by sub-type in England (2020 and 2021)³ and Wales 2022

Denominator	England 2020	Variation 2020	England 2021	Variation 2021	Wales 2022	Variation 2022
All people with NHL	15.8%	Range: 0-63% Median (IQR): 15% (11-20%)	14.4%	Range: 0-75% Median (IQR): 14% (9-18%)	6.0%	Range: 0-50% Median (IQR): 6% (4-8%)
Burkitt lymphoma	12.2%	Range: 0-100% Median (IQR): 0% (0-0%)	12.4%	Range: 0-100% Median (IQR): 0% (0-0%)	0%	Range: 0-0% Median (IQR): 0% (0-0%)
Chronic lymphocytic leukaemia	0.7%	Range: 0-14% Median (IQR): 0% (0-0%)	0.5%	Range: 0-8% Median (IQR): 0% (0-0%)	0%	Range: 0-0% Median (IQR): 0% (0-0%)
Follicular lymphoma	20.9%	Range: 0-70% Median (IQR): 20% (11-27%)	19.5%	Range: 0-100% Median (IQR): 19% (10-27%)	4.3%	Range: 0-17% Median (IQR): 0% (0-5%)
Large B-cell lymphomas	26.3%	Range: 0-100% Median (IQR): 27% (18-35%)	24.5%	Range: 0-100% Median (IQR): 25% (17-33%)	9.0%	Range: 0-50% Median (IQR): 11% (3-15%)
Mantle cell lymphoma	8.0%	Range: 0-100% Median (IQR): 0% (0-13%)	10.0%	Range: 0-100% Median (IQR): 0% (0-17%)	3.7%	Range: 0-25% Median (IQR): 0% (0-0%)

³ Data were impacted by the COVID-19 pandemic and so will be atypical to some degree during 2020-2021



Marginal zone lymphoma	22.8%	Range: 0-100% Median (IQR): 20% (0-33%)	21.7%	Range: 0-100% Median (IQR): 18% (0-31%)	0%	Range: 0-0% Median (IQR): 0% (0-0%)
NHL, NOS	10.9%	Range: 0-51% Median (IQR): 0% (0-15%)	10.1%	Range: 0-50% Median (IQR): 5% (0-15%)	9.1%	Range: 0-50% Median (IQR): 0% (0-8%)
Peripheral T-cell lymphomas	14.9%	Range: 0-100% Median (IQR): 0% (0-25%)	15.6%	Range: 0-100% Median (IQR): 0% (0-25%)	11.1%	Range: 0-100% Median (IQR): 0% (0-0%)
Cutaneous T-cell lymphomas	30.6%	Range: 0-100% Median (IQR): 25% (0-50%)	25.3%	Range: 0-100% Median (IQR): 0% (0-40%)	13.3%	Range: 0-33% Median (IQR): 0% (0-13%)
Other	4.7%	Range: 0-100% Median (IQR): 0% (0-8%)	3.6%	Range: 0-67% Median (IQR): 0% (0-0%)	18.8%	Range: 0-100% Median (IQR): 0% (0-25%)

Supplementary Table 6: Proportion of people diagnosed with NHL receiving radiotherapy within 2 years of diagnosis, reported by sub-type in England (2020 and 2021)⁴. (Wales 2022 not reported due to lack of enough follow-up)

Denominator	England 2020	Variation 2020	England 2021	Variation 2021
All people with NHL	15.4%	Range: 0-62% Median (IQR): 15% (11-20%)	14.3%	Range: 0-75% Median (IQR): 14% (9-18%)
Burkitt lymphoma	12.2%	Range: 0-100% Median (IQR): 0% (0-0%)	12.4%	Range: 0-100% Median (IQR): 0% (0-0%)
Chronic lymphocytic leukaemia	0.7%	Range: 0-14% Median (IQR): 0% (0-0%)	0.5%	Range: 0-8% Median (IQR): 0% (0-0%)
Follicular lymphoma	20.0%	Range: 0-70% Median (IQR): 18% (9-27%)	19.5%	Range: 0-100% Median (IQR): 19% (10-27%)
Large B-cell lymphomas	25.9%	Range: 0-100% Median (IQR): 26% (18-35%)	24.3%	Range: 0-100% Median (IQR): 24% (16-33%)
Mantle cell lymphoma	7.2%	Range: 0-100% Median (IQR): 0% (0-11%)	9.8%	Range: 0-100% Median (IQR): 0% (0-14%)
Marginal zone lymphoma	21.8%	Range: 0-100% Median (IQR): 20% (0-33%)	21.5%	Range: 0-100% Median (IQR): 18% (0-31%)

⁴ Data were impacted by the COVID-19 pandemic and so will be atypical to some degree during 2020-2021



NNHLA

National Non-Hodgkin
Lymphoma Audit

NHL, NOS	10.4%	Range: 0-51% Median (IQR): 0% (0-14%)	9.9%	Range: 0-50% Median (IQR): 5% (0-15%)
Peripheral T-cell lymphomas	14.7%	Range: 0-100% Median (IQR): 0% (0-25%)	15.6%	Range: 0-100% Median (IQR): 0% (0-25%)
Cutaneous T-cell lymphomas	28.6%	Range: 0-100% Median (IQR): 25% (0-50%)	24.7%	Range: 0-100% Median (IQR): 0% (0-40%)
Other	4.7%	Range: 0-100% Median (IQR): 0% (0-8%)	3.5%	Range: 0-67% Median (IQR): 0% (0-0%)

Supplementary Table 7 - One year survival for all people diagnosed with NHL, reported by sub-type in England (2020 and 2021)¹⁵ and Wales (2022)

Denominator	England 2020		England 2021		Wales 2022	
	%	95% CI*	%	95% CI	%	95% CI
Burkitt lymphoma	53.0%	43.5-62.4%	65.3%	56.1-73.7%	n<15	
Chronic lymphocytic leukaemia	88.5%	87.3-89.6%	89.6%	88.5-90.6%	95.5%	91.0-98.2%
Follicular lymphoma	92.3%	91.1-93.4%	92.1%	90.9-93.2%	91.5%	84.8-95.8%
Large B-cell lymphomas	69.3%	67.9-70.7%	70.8%	69.4-72.1%	66.8%	59.8-73.3%
Mantle cell lymphoma	74.8%	70.7-78.5%	80.2%	76.6-83.4%	85.2%	66.3-95.8%
Marginal zone lymphoma	92.0%	90.3-93.5%	93.8%	92.3-95.1%	100%	80.5-100%**
NHL, NOS	65.8%	62.8-68.7%	68.5%	65.7-71.1%	87.9%	71.8-96.6%
Peripheral T-cell lymphomas	55.8%	51.6-60.0%	55.9%	51.9-59.9%	77.8%	52.4-93.6%
Cutaneous T-cell lymphomas	87.8%	83.5-91.3%	88.3%	84.2-91.6%	86.7%	59.5-98.3%
Other	75.6%	72.8-78.2%	77.0%	74.4-79.4%	71.9%	53.3-86.3%

*confidence interval (CI)

**97.5% CI (1-sided)

⁵ Data were impacted by the COVID-19 pandemic and so will be atypical to some degree during 2020-2021